Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of fostamatinib in persistent/chronic immune thrombocytopenic purpura
2013-005453-76Phase 3Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Fostamatinib with Placebo (2 arms). Primary endpoint: Stable platelet response by Week 24. Started Apr 2014; status: completed.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2013-005453-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005453-76.